LIPO OTC
Lipella Pharmaceuticals Inc.
1W: -0.0%
1M: +0.0%
3M: -99.4%
YTD: -99.7%
1Y: -99.9%
3Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$536K
+19.3% ▲
5Y CAGR: -5.0%
Gross Profit
-$3M
-18.8% ▼
Operating Income
-$5M
-7.0% ▼
Net Income
-$5M
-8.6% ▼
EPS (Diluted)
$-4.79
+22.2% ▲
EBITDA
-$5M
-8.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $962K | $259K | $184K | $450K | $536K |
| YoY Growth | +38.4% | -73.0% | -29.0% | +144.2% | +19.3% |
| Cost of Revenue | $976K | $1M | $3M | $3M | $4M |
| Gross Profit | -$14K | -$1M | -$2M | -$3M | -$3M |
| Gross Margin | -1.5% | -461.7% | -1283.4% | -575.9% | -573.7% |
| R&D Expenses | $976K | $1M | $3M | $0 | $0 |
| SG&A Expenses | $43K | $718K | $226K | $2M | $2M |
| Operating Expenses | $43K | $718K | $226K | $2M | $2M |
| Operating Income | -$57K | -$2M | -$3M | -$5M | -$5M |
| Operating Margin | -5.9% | -738.7% | -1406.3% | -1055.6% | -947.2% |
| Interest Expense | $8K | $7K | $10K | $11K | $0 |
| Income Before Tax | -$62K | -$2M | -$3M | -$5M | -$5M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$62K | -$2M | -$3M | -$5M | -$5M |
| Net Margin | -6.4% | -719.3% | -1410.6% | -1027.3% | -935.2% |
| EPS (Diluted) | $-0.23 | $-4.38 | $-5.12 | $-6.16 | $-4.79 |
| EBITDA | -$54K | -$2M | -$3M | -$5M | -$5M |
| Shares Outstanding | 266400 | 426006 | 507578 | 750384 | 1M |